Global Poliomyelitis Vaccation Market Growth 2025-2031
Description
The global Poliomyelitis Vaccation market size is predicted to grow from US$ 156 million in 2025 to US$ 179 million in 2031; it is expected to grow at a CAGR of 2.4% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The poliomyelitis vaccine is a biological preparation used to provide immunity against poliovirus, the causative agent of poliomyelitis (commonly known as polio). There are two main types of polio vaccines: Inactivated Poliovirus Vaccine (IPV), which is injected, and Oral Poliovirus Vaccine (OPV), which is administered orally. These vaccines stimulate the immune system to produce antibodies that neutralize the virus and prevent infection.
The Poliomyelitis Vaccine market is primarily driven by global initiatives aimed at eradicating polio, supported by organizations such as the World Health Organization (WHO), Gavi, and the Global Polio Eradication Initiative (GPEI). Routine immunization programs and mass vaccination campaigns in endemic and high-risk regions continue to sustain demand for both oral polio vaccines (OPV) and inactivated polio vaccines (IPV). Increasing government funding, public health awareness, and international collaboration have significantly boosted vaccination coverage, especially in low- and middle-income countries. Technological advancements in vaccine production and improved supply chain logistics are also contributing to steady market growth.
Despite considerable progress, the market faces challenges such as the emergence of vaccine-derived poliovirus (VDPV) cases, which are associated with the use of OPV in under-immunized populations. This raises concerns about vaccine safety and requires careful transition strategies to IPV. Additionally, logistical barriers—including poor infrastructure, political instability, and limited healthcare access in remote or conflict-affected areas—hamper effective vaccine delivery. Vaccine hesitancy and misinformation in certain communities also threaten immunization efforts. Maintaining funding and momentum in a declining disease landscape remains a critical hurdle to achieving complete eradication and ensuring long-term market stability.
LP Information, Inc. (LPI) ' newest research report, the “Poliomyelitis Vaccation Industry Forecast” looks at past sales and reviews total world Poliomyelitis Vaccation sales in 2024, providing a comprehensive analysis by region and market sector of projected Poliomyelitis Vaccation sales for 2025 through 2031. With Poliomyelitis Vaccation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Poliomyelitis Vaccation industry.
This Insight Report provides a comprehensive analysis of the global Poliomyelitis Vaccation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Poliomyelitis Vaccation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Poliomyelitis Vaccation market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Poliomyelitis Vaccation and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Poliomyelitis Vaccation.
This report presents a comprehensive overview, market shares, and growth opportunities of Poliomyelitis Vaccation market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
OPV
IPV
Segmentation by Application:
Hospitals
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi
GSK
Bibcol
Serum Institute (Bilthoven Biologicals)
Tiantan Biological
IMBCA
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
SINOVAC
Key Questions Addressed in this Report
What is the 10-year outlook for the global Poliomyelitis Vaccation market?
What factors are driving Poliomyelitis Vaccation market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Poliomyelitis Vaccation market opportunities vary by end market size?
How does Poliomyelitis Vaccation break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The poliomyelitis vaccine is a biological preparation used to provide immunity against poliovirus, the causative agent of poliomyelitis (commonly known as polio). There are two main types of polio vaccines: Inactivated Poliovirus Vaccine (IPV), which is injected, and Oral Poliovirus Vaccine (OPV), which is administered orally. These vaccines stimulate the immune system to produce antibodies that neutralize the virus and prevent infection.
The Poliomyelitis Vaccine market is primarily driven by global initiatives aimed at eradicating polio, supported by organizations such as the World Health Organization (WHO), Gavi, and the Global Polio Eradication Initiative (GPEI). Routine immunization programs and mass vaccination campaigns in endemic and high-risk regions continue to sustain demand for both oral polio vaccines (OPV) and inactivated polio vaccines (IPV). Increasing government funding, public health awareness, and international collaboration have significantly boosted vaccination coverage, especially in low- and middle-income countries. Technological advancements in vaccine production and improved supply chain logistics are also contributing to steady market growth.
Despite considerable progress, the market faces challenges such as the emergence of vaccine-derived poliovirus (VDPV) cases, which are associated with the use of OPV in under-immunized populations. This raises concerns about vaccine safety and requires careful transition strategies to IPV. Additionally, logistical barriers—including poor infrastructure, political instability, and limited healthcare access in remote or conflict-affected areas—hamper effective vaccine delivery. Vaccine hesitancy and misinformation in certain communities also threaten immunization efforts. Maintaining funding and momentum in a declining disease landscape remains a critical hurdle to achieving complete eradication and ensuring long-term market stability.
LP Information, Inc. (LPI) ' newest research report, the “Poliomyelitis Vaccation Industry Forecast” looks at past sales and reviews total world Poliomyelitis Vaccation sales in 2024, providing a comprehensive analysis by region and market sector of projected Poliomyelitis Vaccation sales for 2025 through 2031. With Poliomyelitis Vaccation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Poliomyelitis Vaccation industry.
This Insight Report provides a comprehensive analysis of the global Poliomyelitis Vaccation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Poliomyelitis Vaccation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Poliomyelitis Vaccation market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Poliomyelitis Vaccation and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Poliomyelitis Vaccation.
This report presents a comprehensive overview, market shares, and growth opportunities of Poliomyelitis Vaccation market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
OPV
IPV
Segmentation by Application:
Hospitals
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi
GSK
Bibcol
Serum Institute (Bilthoven Biologicals)
Tiantan Biological
IMBCA
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
SINOVAC
Key Questions Addressed in this Report
What is the 10-year outlook for the global Poliomyelitis Vaccation market?
What factors are driving Poliomyelitis Vaccation market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Poliomyelitis Vaccation market opportunities vary by end market size?
How does Poliomyelitis Vaccation break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
103 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Poliomyelitis Vaccation by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Poliomyelitis Vaccation by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
